Cipla reports steady Q1 revenue, robust profit growth

Cipla reported Q1 FY26 revenue of INR6,957 crores, a 4% year-over-year increase, with an EBITDA margin of 25.6%. The One India business grew 6% year-over-year, exceeding INR3,000 crores for the first time in an opening financial quarter.

In North America, quarterly revenue reached $226 million, with Albuterol maintaining its #1 market position. Profit after tax grew 10.2% year-over-year to INR1,298 crores, an 18.7% sales margin.

The company's R&D investments totaled INR432 crores, representing 6.2% of revenue.